Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Key challenges for Health and Care are Staff, Beds and Costs. These exacerbate, breaches, delays and overall efficiency. Our web based innovation ‘VIDIMO’ addresses all of these by bringing Health and Care organisations together 'in a virtual sense'.

Overview of Innovation:
VIDIMO - A real-time, web based platform specifically designed to target key operational challenges. Its primary audience is Health and Care professionals. At its core, VIDIMO is about reducing patient waiting times, Delayed Transfers of Care and Manual Overheads endured by front-line staff whilst improving overall visibility, efficiency, collaboration and patient flow across multiple care settings.

In essence, VIDIMO takes the Internet of Things (IoT) approach and applies it to the Care World:
 
Bringing Ambulance Trusts and Hospitals together, by delivering real-time visibility of hospital status and capacity to Ambulance Trusts and their crews to:
  • Rreduce waiting times for crews and patients
  • Reduce the £78.4m spend on private ambulance companies
  • Remove the risk of redirects altogether.
Bringing Acute hosiptals and Social Care Boroughs together by providing:
  • Real-time visibility of available beds within and beyond the organisational boundary and across multiple care settings.
  • A collaborative platform to monitor, reduce and manage Delays more effectively.
  • Reduce penalty tariffs
  • Significantly reduce manual overheads.
Bringing Social Care and other Care organisations together, allowing much greater flexibility and efficiency in locating appropriate care beds and services regardless of patient location. VIDIMO provides:
  • The mechanism for Care Homes (large or small), to make available bed assets visible to the widest possible Health and Care audience. This includes Rehab Centres, Extra Sheltered and D2A partner initiatives.
  • Provides Social Care and CCG Brokerage Teams with a single platform of visibility and management.

VIDIMO's more clever together approach is a step change from the traditional silo'd approach and provides more intelligent ways of working.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Reduction in Ambulance crew wait times:
Ambulance Trusts: Lengthy A&E waits or time costly redirects from one hospital to another are costing Trusts £78.4m on private ambulance companies to help them cope with these challenges. Redirects are not only bad for crews but places additional risk on patient safety.
Number of Ambulance redirects (2017-18): 500+
Time lost in a single day by waiting Ambulance crews (Jan 2018):  800 hrs
Costs to the NHS in patient delays this winter 2017/18: - 75,000 hrs
Source: Nuffield Trust
Benefit: removal of redirects altogether.
Reduction in Ambualnce Trusts £78.4m spend on private ambulance companies
Potential reduction in ambualnce wait times meaning greater patient throughput per crew.

Reduced delays for Acute Hospitals and Social Care:
For every 1% reduction in Delays:
An additional 2000 patients would leave hospital on time.
Health and Care could reclaim 22,000 delay days and reduce their penalty tariffs by £12m.

Reduction in Manual overheads and associated costs savings.
Multiple Situation Reports, Bed management meetings and Delay Report meetings are just the tip of the iceburg when it comes to manual overheads. Add to that the effort involved in locating and appropriate care bed or service and it all adds up to a staggering 1.6m person days (equiv to an additional 9000 full-time staff) or £270m worth of care professionals time, time that could be better spend on patient. Our analysis shows that it typically takes 10-15 minutes(600-900) seconds to locate an appropriate available bed using current mothds and approaches. Using VIDIMO the task would take that length of time in seconds to locate every available bed in the region. That equates to a circa 6000% efficiency increase.
Benefit: Refocus upto 1.4m staff days back to direct patient care. CCG & Social Care brokerage teams, in fact all parties, would have unprecedented visibility of available beds across multiple care settings, with no phone calls, emails or running round in ever deceasing circles.

Reduction in the £1bn Breach/readmit penalty tariffs
Benefit:
for every 1% reduction - thousands of patients wait less time to receive appropriate level of care; reduction in NHS penalty tariffs by £10m.
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Health and Social  Care would have increaced real-time exposure to Care Home and/or care service providors regardless of size.
Increased exposure of service provision and care homes.
More efficient services from Social Care
Greater value for money.
 
Current and planned activity: 
We have initiated contact with CLAHRC, NHIR (i4i) but have yet to receive any response.
We have initiated contact with Prof. Lyndon Smith (University of the West of England) wrt 3D facial
recognition but have yet to receive any formal response.
Predictive analytics - Scheduled to meet with Kings College London.
We have initiated dialog with several AHSN's
Accepted on the Innovate UK testbed initiative (April 2018)
Reached out to all STP's
Reached out to 24 CCG's
Reached out to NIA
Reached out to ADASS national and regional
 
What is the intellectual property status of your innovation?:
We already have provision in place for our intellectual property.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Paul Rylance 02/10/2018 - 17:09 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Liva Healthcare can reverse chronic lifestyle diseases, such as Type 2 Diabetes through digital lifestyle coaching. Liva is a hybrid model of technology and human intervention that drives long term behaviour and lifestyle changes
Overview of Innovation:
 
Founded in 2014, Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management.  
  
Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England, AXA PPP Healthcare and Copenhagen Municipality.  
  
Liva Healthcare’s platform facilitates ongoing personalised health coaching through an intuitive app, building strong bond between coach, GP and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity and heart disease, by driving behaviour change.   
   
Currently being used in Denmark, UK and Sweden, the app is multilingual across several languages. It has proven to work efficiently across all socio-economic backgrounds and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviours stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes.  
  
Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform, or as a turn-key solution, dependent on client specifications.  
  
Liva Healthcare has offices in Copenhagen, Denmark and London, UK. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
By helping to both prevent and cure chronic lifestyle diseases, Liva consequently relieves the cost pressures on healthcare systems.  Unhealthy lifestyles lead to significant cost pressures on healthcare systems. For example, in the UK it is claimed that Type 2 diabetes costs the National Health Service (NHS) £8.8 billion per year, which equates to almost 9pc of its annual budget and causes 20,000 early deaths per year. In addition, it is estimated that obesity costs the NHS over £5 billion per year.   
 
The platform also allows health professionals to monitor up to 400 patients at the same time. This enables the NHS to save costs as the digital health tool can help patients come off medication. It also drives efficiency by enabling more patients to be monitored.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The primary benefit that Liva Healthcare provides patients with is the opportunity make long-term lifestyle changes to diet and exercise, with the help of a personal health coach, that can prevent or remove their lifestyle disease (e.g. Type 2 diabetes, obesity or heart disease).  
 
Liva was designed to help prevent and reverse chronic diseases caused by unhealthy modern lifestyles, such as Type 2 diabetes and heart disease, both of which are often caused and affected by weight gain. The app is based on clinical research that has shown lifestyle interventions can lead to long-term lifestyle change and help patients reduce their risk of the disease or enter remission by losing weight.  
 
For example, Liva Healthcare monitored the progress of 136 patients using its digital healthcare app to prevent and roll back Type 2 diabetes over a nine-month period. Over the period, 82% of the patients (112) lost weight, losing an average of 6.3kg, demonstrating signs of a successful lifestyle intervention.  
Current and planned activity: 
In response to the crisis the NHS chose Liva as one of five providers to tackle Type 2 diabetes using digital innovations. GPs can now refer patients at risk of Type 2 diabetes in North East London, Humber, Coast and Vale to use the Liva app. Patients are given a personal health coach and an app to help monitor and track their health goals. The app is based on strong evidence that has shown lifestyle interventions, delivered digitally, can lead to long term lifestyle change and help patients with, or at risk of, Type 2 diabetes reduce their risk of the disease or enter remission. Liva holds the firm belief that prevention is better than cure. Though, in many instances, its platform has been proven to facilitate both. 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Simon Pickup 01/10/2018 - 14:47 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Do you feel the frustration of having a really great idea, stonewalled by the people you’re trying to help?
WCBL is a training and coaching package we're developing to help Healthcare Transformation champions resolve the people-factor issues they face
Overview of Innovation:
What is the WCBL Package?
  • There are existing courses to address the rational, process approach to change
  • This package complement those, by addressing the human, emotional side of change.
  • We will use a people-centred approach, focusing on key aspects of how we think, communicate and build resilience as individuals.
  • The package will include various coaching methods, using traditional coaching and NLP communication tools as most appropriate.
  • The package will consist of two main elements:
    • A Digital Coaching & Training Course to bring the delegates up to an initial capability;
    • An Ongoing Support facility to help the delegates apply their newfound skills in practice and to facilitate resolution of more challenging issues.
Course Structure
The course is made up of a number of live sessions, mainly provided digitally by webinar, sandwiched with initial and final sessions face-to-face.
WCBL Toolkit: The live course elements are supplemented by an online digital ‘toolkit’ of useful video and written material, available to the delegates throughout. 
WCBL – Ongoing Support
Course ‘graduates’ will have gained new skills in resolving people-factor issues.  Ongoing support facilitates the transition to using these in practice.  This support also makes use of a mix of digital online and direct elements.

Package Aims
  • To empower delegates with understanding and rapport, so as to address human and emotional aspects of transformation programmes.
  • To build their resilience, providing the energy and motivation to resolve such issues.
What are the initial course Measurable Objectives?
  • To enable transformation ‘champions’ to resolve c.80% of the people-factor (non-functional, emotional, ‘illogical’) issues that they come across.
What are the ongoing support Measurable Objectives?
  • To enable transformation ‘champions’ to resolve nearly all of the remaining, more challenging people-factor issues that they come across.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Digital health / Innovation and adoption
Benefit to NHS:
The NHS and local councils are developing and implementing shared proposals to improve health and care in every part of England. Over the next few years, these represent the biggest national move to join up care in any major western country.” A large part of this work is underpinned by several digital health initiatives - WCBL provides the necessary skills and capabilities for NHS Transformation Teams to actually deliver what they are intended to.
Initial Review Rating
3.20 (2 ratings)
Benefit to WM population:
WIth digital health initiatives successfully in place, the WM population will have much better access to timely patient care, often in the comfort of their own home.  WCBL will allow these initiatives to succeed much more quickly and effectively.
Current and planned activity: 
Have held some discussions with healthcare agencies in the NW. 

Currently, have just completed Proof of Concept trials with with webinar taster sessions and WCBL Toolkit 'appetisers', to assess feasibility and hone the approach.  The results have been very promising, and are to be discussed with the healthcare agencies once written up.
What is the intellectual property status of your innovation?:
The coaching and training elements are, in themselves, generally available.  The specific mix of techniques and the course syllabus are Evsco Ltd commercial IPR. The webinar and toolbox platforms are commercially available (currently WebEx and Teachable).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Andrew Evans 18/09/2018 - 18:39 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Teleswallowing enables poorly people to be seen more rapidly by specialists and improves staff productivity threefold
Overview of Innovation:
Teleswallowing is an approach using technology whereby a speech and language therapist can run a virtual clinic to triage, manage and review his/her patients with eating and drinking problems (dysphagia).  Teleswallowing Ltd staff train the carers within residential and care settings to be able to link remotely with speech therapists to provide rapid access to specialist skills to avoid unnecessary distress, avoidable deterioration and hospital admissions.  Speech and Language Therapy is a scarce resource and the waiting lists to see a specialist are long.  The use of Teleswallowing technology prevents vulnerable people suffering and can be used as an out of hours/weekend cover approach. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption
Benefit to NHS:
I developed the approach at Blackpool where it is used; NWAHSN sponsored its development in Cheshire and West Hants CCG has commissioned the use in Southampton.  We have proven, through clinical trials supervised by Dr Liz Boaden from the University of Central Lancashire, that the approach increases staff productivity three fold and saves approximately £60 per assessment.  University College London used the approach in a workforce scoping project and found that 10.38 weeks of speech therapy time could be saved by using Teleswallowing.  Please see all evaluations on www.teleswallowing.com
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Many SLTs (speech and language therapists) are women working part time and below their level of training due to having child care or elderly parent responsibilities.  We would like to upscale our approach so that we not only offer training in the approach, but are able to deliver commissions for weekend/out of hours cover remotely, giving the opportunity for West Midland SLTs to work from home at hours best suited to their life and also help reduce the waiting times for sick people needing dysphagia assessments.  The SLTs would earn a better income, use their hard earned skills and be of benefit to the health system - by utilising a modern, digital approach.
Current and planned activity: 
The approach is used at Blackpool Teaching Hospitals, Cheshire and West Hampshire CCG.  I am bidding for a Women in Innovation award (Innovate UK) in order to develop the approach into an e-learning package, an app which then will be a digital clinic portal whereby SLTs will book in their availability to fulfil contracts remotely.  The SLTs will also be able to take advantage of the e-learning videos/second opinions/webinars which I intend to develop if I win the funding which goes with the Women in Innovation bid.
What is the intellectual property status of your innovation?:
Teleswallowing Ltd is a limited company and we have registered the name as ours.  The intellectual property is ours.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Veronica Southern 09/09/2018 - 15:59 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
People living with dysphagia - swallowing difficulty - need drinks that flow slowly.
We are to help them make Slõ Drinks for all their healthcare needs.
Overview of Innovation:
For people with dysphagia, ordinary drinks like you and I have flow to fast for them to cope with.
As a result they choke when they drink, which can lead to aspiration pneumonia, malnutrition and readmission.

To prevent this they must make all their drinks flow slowly and at specific speeds. This is done by adding thickener using a scoop. However, it is very difficult to add the right amount with a scoop and make every drinks safe to swallow.

We have therefore taken all the drinks someone could need or want, calculated the amount required and put that in a sachet. Then sachet contents are simply mixed with the volume of liquid we specify to change drinks for hydration into Slõ Juice, Slõ Tea or Slõ Fizzy. Drinks for medication such as soluble laxatives into Slõ Solulax and drinks for relaxing with into Slõ Wine, Slõ Beer and Slõ Cider.

Oral Nutritional Supplements (ONS) are different.
 
Powdered and ready to drink ONS are difficult to impossible to thicken safely with starch and gum thickeners. Consequently, health care professionals prefer to reduce risks by prescribing Fresubin and Nutilis Complete pre-thickened ready-to-drink ONS.
 
They cost £2.20 each and the NHS spent £4,500,000 on them over the last year.
 
The innovation I want to introduce to your CCG's is an alternative which provide all the safety of a ready to drink ONS for the price of a powdered one. Called Slõ Milkshakes+ they are the 1st pre-thickened and powdered protein rich ONS on prescription.

Costing 84p each, they provide a saving per prescription of £ 80+ per month or £ 900+ per patient
per year. If Slõ Milkshakes+ were used during the same period they would have saved a massive
£ 2,800,000.

They also provide huge environmental savings. Slõ Milkshakes+ are presented in powder form in sachets. Not using single use plastic bottles, dramatically reduces the CO2 impact of manufacture, delivery and recycling. Our sachets can even be incinerated and used in energy recovery plan.
 
Just as importantly, Slõ Milkshakes+ are drinkable. Made with whole milk from the fridge, they taste fresh, do not taste too sweet or have a metallic aftertaste. Ultimately, that makes it easier gain compliance and maintain patient’s oral nutritional intake.
 
It’s for all these reasons they are being added to Formularies across the UK and why I want to introduce Slõ Milkshakes+ with the aim of introducing your CCG’s to
Slõ Milkshakes+.
 
There is additional useful information here: www.slodrinks.com/ons



 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Innovation and adoption / Person centred care
Benefit to NHS:
Slõ Milkshakes+ have been created to help reduce financial and environmental costs whilst improving patient outcomes - now and in the future.

Just focusing on costs - as previously stated, Slõ Milkshakes+ save £80.00+ per prescription. That may not seem like a huge amount, but the cumulative saving is huge.
 
From March 2017 to March 2018, the NHS spent £ 4,500,000 on Fresubin and Nutilis Pre-thickened ready to drink ONS. In comparison to spend on medications that is not a lot. However, spend on products for dysphagia is going to increase for two key reasons.
 
Firstly, healthcare professionals are not seeking to diagnose dysphagia. As recently as two months ago the Doctors dedicated website www.gponline.com made identifying Dysphagia a Red Flag topic.
The reason – they now recognise the impact dysphagia has on treating the primary condition.
 
If a patient is diagnosed with it every medication, drink and supplement has to be altered so it can be swallowed safely without inducing aspiration.
 
Secondly, it is a secondary symptom of 127 conditions including; Stroke, Alzheimer’s, Head and Neck Cancer and Motor Neurone Disease. These conditions present themselves typically in the elderly and dysphagia affects 10-12% of those over 50 – an increasingly large proportion of our population.   
 
We can therefore predict with certainty, if the spend on ready-to-drink Fresubin and Nutilis just remains the same the accumulative spend in 5 years will be £ 22,500,000.
 
By making Slõ Milkshakes+ a 1st line response for dysphagia now over the same period the cost of prescribing Slõ Milkshakes+ would only be £ 8,148,000, saving £ 14,352,000!

 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
Slõ Milkshakes+ make a positive impact to the health and wealth of the region through saving: saving patients from the risks of aspiration pneumonia, malnutrition and readmission; saving the CCG’s and healthcare professionals from unnecessary spend on expensive ONS for this patient group.
 
 
By providing a safe and reliable method to make safer to swallow ONS, Slõ Milkshakes+ reduce the risks of patients acquiring complications.
 
Patients will find it easy to consume the prescribed number of Slõ Milkshakes+ because they can actually drink them. They know they flow at the right speed and don’t need to worry about choking or embarrassing themselves in front of others – including their spouse.
 
When made Slõ Milkshakes+ look like ordinary milkshakes. No one can tell it flows slowly. It therefore doesn’t highlight their condition; gives them a feeling of inclusion.
 
Ultimately this makes for a better patient experience and improves compliance, which in turn saves them from the risks of malnutrition and re-admission.
 
Avoiding re-admission will save all the financial and patient costs associated with it, but and more importantly Slõ Milkshakes+ keep the costs of providing adequate nutrition in the Community to a minimum, saving CCG’s and healthcare professionals unnecessary spend on finances and time.
 
The financial savings are easy to quantify. Slõ Milkshakes+ will save £ 80+ per prescription every time a prescription is written for them instead of a ready to drink ONS.
 
Your CCG’s can quantify those savings by adding up the number of Fresubin and Nutilis Complete prescribed, multiplying by 84p (the Slõ Milkshake+ cost) and comparing the two.
 
Further savings are achieved by presenting Slõ Milkshakes+ in boxes of 7. A prescription can be written for just 7 sachets – a weeks’ supply – to see if a patient likes them. If they do, a larger prescription for one month’s supply can be written.
 
It’s also important to highlight the time saved, specifically time spent on implementation and training
in Nursing Home and Care Facilities where the majority of those with dysphagia reside.
 
These facilities typically have a high turnover of staff and many do not have English as a first language. As a direct result every Slõ Milkshake+ sachet features written and pictorial instructions to make sure they are always made correctly.
 
This makes training quick, easy and efficient, allowing health care professionals to focus on other important healthcare needs.
 
Current and planned activity: 
We are in constant contact with all divisions and levels of the NHS across the UK.
 
Our primary contacts have been healthcare professionals in Acute Hospitals, their colleagues in the Community and Doctors who have prescribed Slõ Milkshakes+.

During 2018 we have been focusing establishing relationships with CCG’s and their Medicines Management Team. We have been able to make contact via some Prescribing Support Dietitians but this has been difficult and slow.
 
This is why I have contacted all other ASHN's and yourselves - with a view to meeting your CCG’s and showing them how Slõ Milkshakes+ can help them and their patients.
What is the intellectual property status of your innovation?:
Our Competitors are giant Pharmacutical Companies and therefore a patent would be difficult to impossible to defend.
As a result I have had the Slõ Brand is trademarked here and in various Counties around the world.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Mathew Done 10/08/2018 - 10:17 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 15:11 Publish 4 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Catheters cause 250,000 serious infections, 3,000 deaths & up to £500m in healthcare costs a year research reports. UroShield prevents bacterial biofilm formation, increases antibiotic efficacy & decreases pain & discomfort of urinary catheter use.

Overview of Innovation:
90,000 Britons are fitted with a urinary catheter each year. Catheters are essential for a wide range of conditions that compromise the ability to empty the bladder effectively, such as prostate cancer patients and those with incontinence and neurological conditions like multiple sclerosis and spinal injury.
 
Indwelling catheters serve as an environment for bacterial attachment, biofilm formation and subsequent urinary tract infections (UTI). Biofilm formation is a thick, bacterial ‘glue’ that sticks to the surface of the catheter plastic and is highly resistant to antibiotics, making infections difficult to treat. Such catheter-acquired infections are one of the most common iatrogenic complications and may lead to increased mortality rates, extended hospital stays and increased medical costs for healthcare providers.
 
UroShield uses soundwaves to ‘shake’ away bacteria, protecting patients from painful and potentially life-threatening bladder infections. It is composed of 2 components: A disposable actuator which clips onto the external portion of the catheter and a portable battery powered driver.



The device sends out low-frequency ultrasound waves (Surface Acoustic Waves) which run longitudinally along both the inner and outer surfaces of the catheter. These surface acoustic waves prevent bacteria from docking and adhering to the catheter and subsequently prevent the formation of biofilm.
 
If there is a biofilm already present or one does form, the ultrasound waves help to break up the normally impenetrable biofilm matrix to allow access of the antibiotic to the biofilm. This increases the antibiotic efficacy by working synergistically so that patients may have a shorter course and lower dose of antibiotics.


In addition, independent studies from leading Universities have shown that the UroShield device enhances the immune systems’ ability to fight biofilm. In further studies the Uroshield device achieved a 90% reduction in the presence of common bacteria most likely to cause infection including E. coli and Staphylococcus epidermidis.
 
The action of the ultrasonic waves on the surfaces of the catheter interfere with the attachment of bacteria, prevents infections developing, reduces catheter encrustation and blockages and decreases or eliminates the need for antibiotics, reducing risk and improving patient outcomes. This in turn reduces the costs associated with indwelling catheter complications that may lead to increased medication and extended hospital stays.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:
Reducing health care-associated infections (HCAIs) remains high on the Government’s
safety and quality agenda and in the general public’s expectations for quality of care.
 
Patients with invasive devices such as urinary catheters are at a greater risk of developing a HCAI (NICE, 2012). In addition to increased costs, each one of these infections means additional use of NHS resources, greater patient discomfort and a decrease in patient safety.
 
UroShield is a breakthrough device to prevent or treat catheter-related trauma.
 

 
Once the urinary catheter has been placed into the patient’s bladder, the actuator is clipped on the extracorporeal part of the catheter and the device is activated. UroShield harnesses the known therapeutic effects of ultrasound such as tissue healing and muscle relaxation to significantly decrease catheter-associated pain and discomfort. This is extremely easy for nurses to use and maintain, with a simple clip around the catheter to be changed monthly and disposed of in standard waste.
 
UroShield could have huge implications for reducing A&E admission rates as 224,670 admissions for UTIs were reported in 2009 and 2010 and since then numbers have continued to increase, with 43-56% of all UTIs being associated with indwelling. Between 2013/2014, the NHS spent £434 million treating 184,000 hospital admissions for a UTI.
 
UroShield could play a key role in achieving CQUIN targets for CAUTI rates and the reduction in E. coli Bloodstream Infections through the initial prevention of infection.
 
E. coli is one of the main pathogens responsible for causing UTIs and CAUTI, of which Gram-negative CAUTIs are often a source of bacteraemia. E. coli account for 55% of all BSIs and of these UTIs are responsible for 45% of E. coli BSIs. E. coli BSIs have increased by 20% over the last five years and the trend is still rising, which is of grave concern.
 
E. coli BSI are therefore a huge patient safety issue and are set to cost the NHS £2.3 billion by 2018. These contributed to over 5,500 NHS patient deaths in 2015 and there is £45 million quality premium which is incentivised by Ruth May to reduce healthcare associated Gram-negative BSIs by 50% across the NHS by 2021. The goals are to: prevent the need for antibacterial prescription, to reduce the dose or length or antibiotics as a minimum, and to reduce hospital admissions and HCAIs.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Over 1 million patients a year have a catheter for a short time while in hospital & those using them at home for longer periods have them changed every 3 months & infections can be missed between changes.
 
An untreated urinary tract infection (UTI) may spread to the kidney, causing more pain & illness & lead to sepsis, a life-threatening reaction to an infection.
 
Long-term catheterisation carries a significant risk of symptomatic UTI, which can lead to serious complications such as bloodstream infections (NICE 2012). The diagnosis of a CAUTI increases the use of antibiotics which will increase the burden & development of antimicrobial resistance (DH, 2007).
 
Recurrent lower UTIs have a detrimental effect on patients quality of life. Patients experience a psychological burden because they live with the anxiety of sudden acute episodes. The resulting social handicap is known to induce feelings of self-devaluation or culpability, which can lead to clinical symptoms of depression.
 
UroShield could protect thousands of patients from painful & potentially life-threatening bladder infections reducing the psychological burden & anxiety patients experience.
 
The innovation is currently being trialled in NHS hospitals with leading urologists including a consultant & surgeon at the Royal Marsden in London describing the device as ‘game-changing’.
 
Uroshield comprises an electronic driver (8-hour battery life) weighing 5g & a disposable clip that fits around the catheter tube, the driver transmits continuous ultrasound waves to the clip via a small cable. The rechargeable device can be switched on & off & a small screen on the driver indicates power supply & battery life.
 
Clinical trials have shown the acoustic sound waves generated by the UroShield device along the urinary catheter result in a significant decrease in catheter-associated pain & discomfort.
 
Click the image below to read the full article.


 
UroShield significantly reduces bladder washouts in catheterised patients & thus could reduce visits from district nurses to generate significant cost & time savings. For example, one patient required daily bladder washouts & since UroShield no longer requires any at all. Patients can have greatly extended catheter life, reducing the frequency of catheter change & maintenance & nurse callout time associated with this. Alongside freeing time & resources, UroShield could also assist Infection Prevention Nurses in achieving CQUIN targets based on catheter-associated infection rates.
Current and planned activity: 
We are speaking with over 80 primary and secondary care sites with regards to UroShield. We currently have 6 NHS sites evaluating UroShield in small scale patient service evaluations alongside a double-blind randomised controlled trial producing positive data proving the efficacy of UroShield.
 
We are also working to provide Health Economic Data which will further support the use of UroShield across various healthcare settings. To support this we are looking to work with a NHS partner in the West Midlands to undertake a small-scale (service) real-life evaluation of UroShield to demonstrate patient and fiscal benefits of using the device.
 
UroShield can help you to support the delivery of the national ‘reducing the impact of serious infections (Antimicrobial Resistance and Sepsis’ CQUIN by creating a new, improved pattern of care for patients, reducing their risk of painful and potentially life-threatening bladder infections.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Alex Ackernley 05/07/2018 - 08:41 Publish 4 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
We work to reduce unplanned hospital admissions. Proactive Health Coaching helps patients to better control their health and thus reducing non-elective care. Engaged patients seek care at the right place, helping the NHS use its resources efficiently
Overview of Innovation:
Health Navigator is dedicated to improving patients’ lives through digitally supported health coaching at scale which is underpinned by robust scientific evidence.
 
Our forward strategy includes delivering an effortless patient experience and a focus on the development of a range of digitised services. To enable this, we are transforming the ways in which we deliver our services.

One of our services is Proactive Health Coaching (PHC). PHC is a telephone-based health management service that improves patient health and quality of life, while ensuring that healthcare resources are spent as efficiently as possible.
 
PHC provides non-medical patient support to help patients understand their chronic conditions, plan their care and navigate an often-complex healthcare system.
 
By identifying those likely to see future avoidable unplanned care, a coach is able to proactively support the patient. Support including helping to stabilise their condition, feel more confident in managing their conditions and navigating the often-complex health care system, thus reducing the risk of unplanned care.
 

 
Our model is evidence-based and grounded in scientific research, supported by several successful randomised trials. In summary PHC uses a patented combined approach of:

1) a complex risk predicting algorithm to forward predict on a daily basis, patients which are at high risk of a non-elective admissions
2) to then provide a programme of individualised care to those at high risk using our nurse led case management programme.

The unique combination of the two provides the outcomes summarised below.

The end goals are:

1) To improve patient outcomes and reduce healthcare utilisation
2) To deliver operational efficiencies across the whole health system by reducing demand and avoidable admissions
3) To deliver a significant cost saving

Our company has successfully delivered this service to over 33000 patients in Sweden where we also conducted a randomised control trial with 12000 patients which statistically showed a reduction in healthcare utilisation by 30-50%. These results were published in the EJEM in 2013 and 2015.

We are now conducting another RCT in the UK with The Nuffield Trust as the principal investigator to replicate the Swedish results. We have over 7 CCGS already working with us and two years’ worth of data is showing statistically significant reductions of 30% in non-elective admissions and 36% in A&E attendances in the intervention groups.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:

The intervention is co-created and patient goal focused.
 
First we get to know the patient during a face-to-face meeting with a health coach where we review the challenges the patient faces, agree on some shared goals and make a plan for the future.
 
Over the next 6-9 months, the coach and patient have regular contact as the patient continues to make progress. Over time, the patient becomes more confident about managing their own condition and seeking the right care, at the right time.
 
By the end of their coaching program most patients feel confident to continue independently. By this time, the risk of seeking avoidable unplanned medical care has decreased significantly.
 
Proactive Health Coaching is being delivered together with various CCG partners in England and will be evaluated by the Nuffield Trust on a yearly basis.
 
By supporting patients with weekly coaching calls, the randomised control trial with NHS Vale and York CCG is already showing high levels of improved patient experience, a reduction in attendances at A&E and fewer admissions to hospital. Patients being supported by their health coaching intervention are also reporting more confidence in the management of their conditions.
 
From a recent NHS Confed case study (June 2017), results collated by NHS Vale of York CCG are currently being evaluated and published by the Nuffield Trust, an independent health charity. In this early assessment of the trial, this case study covers 183 patients, of which 121 patients have had the support of a health coach, has yielded savings per patient in the first year of the intervention of £1,034 less than the control group. This means that the service is already close to break-even in its first year, as it costs £1,200 per person for a two-year intervention.
 
Moreover, there are the associated operational benefits from taking activity out of the system. In particular, the intervention group has had 63% fewer non-elective admissions and 60% fewer A&E attendances. The number of bed days was 17% less than the control group. The results also provide evidence of relevance, spread and replicability, with the initiative being easy to replicate, even in financially challenged care economies.
 
Recent results show a statistical reduction of 30% and 36% in non-electives and A&E attendances respectively. Since 2010 the Proactive Health Coaching service has helped over 15,000 patients to achieve better health, with 90% reporting that their health coach has improved their quality of life.
 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Proactive Health Coaching helps increasingly stressed health care systems.
 
We know that receiving the right care, at the right time is crucial to effective care, but navigating a highly complex health care system can often leave patients feeling overwhelmed or under treated, leading to repeated unplanned hospital visits or admissions. The stress on the system is apparent within emergency departments in the UK that are under increasing pressure as visitor numbers continue to rise.
 
But reports show that a lot of the health care we provide is avoidable. What’s more, the vast majority of resources end up funnelling to a small number of people. Health Navigator provides an evidence-based solution through non-medical, intensive, short-term coaching for patients with diverse and often complex health needs. Coaching results in reduced costs for this care heavy group and frees up much needed acute resources.
 
At Health Navigator, we have experienced nurses and AHPS working as health coaches who provide the support needed to understand health conditions, plan care, and enable patients to become more confident in managing their individual health needs.
 

 
The intervention is delivered in four phases.
 
Patient Identification: Identification through a predictive model to ensure the right intervention, to the right patients, at the right time.
 
Intervention: Non-clinical telephone-based intervention to empower the patient and improve ordinary care – so that avoidable care can be proactively prevented.
 
Evaluation / Monitoring: Continuous monitoring to ensure resource-efficient effort per patient.
 
Discharge: When patient is no longer in need of support a decision is jointly taken by patient and health coach to end contact.
 
Personal Health Coaching has the ability to significantly reduce avoidable healthcare consumption in the West Midlands, reducing costs and freeing up much needed acute resources. Latest results show a statistical reduction of 30% and 36% in non-electives and A&E attendances respectively. If scaled up across the West Midlands this could significantly reduce health inequalities, improve patient outcomes, reduce operational pressures whilst delivering a financial saving.
 
We are currently working with 3 CCG’s in the region and are seeking additional sites in the West Midlands to join our randomised control trial.

Current and planned activity: 
This is an exciting time for Health Navigator UK. We are encouraged by the progress we are making and are delighted to have secured a number of significant contracts to deliver new and innovative healthcare services in the UK.
 
Proactive Health Coaching is being delivered together with seven CCG partners in England and will be evaluated by the Nuffield Trust on a yearly basis. We are currently showing statistically significant reductions in the intervention group compared to the control of 30% in non electives and 36% in A&E attendances.
 
We are at the start of a significant growth phase but acknowledge we cannot do it alone and we are seeking additional sites in the West Midlands to work with.
 
If you would like to explore this opportunity please get in touch.
What is the intellectual property status of your innovation?:
Held by Health Navigator UK Ltd
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Ravinder Sandhu 21/05/2018 - 10:52 Publish 1 comment
4.3
3
Votes
-99999
Innovation 'Elevator Pitch':
We're developing an Autonomous Patient Observation System (APOS) which will automate patient observation in any environment.
Overview of Innovation:
We're a start-up creating an Autonomous Patient Observation System (APOS) which collects user data from facial expressions, physical activities, gait analysis, user habbits, agression and agitation, and so on. We're looking to provide a fully autonomous device which can gather all that data and generate reports, insights, classifications and statistical analysis.
The APOS device is the size of a can of beer, and is extremely easy to use; just register the patient, and let it work for as long as you need to. It does not use cameras, but only lazer depth sensors, and the final product will be low-cost. The APOS device aims to provide impartial, aggregated meta-data and insights, in order to make assessments and evaluations simpler, faster and more accurate.
We're focusing on a Dementia Observation System, and are also interested in frailty indexing. We will be releasing the beta product end of September, and if you would like to test one for free, please contact us.

You may find more information on our website: https://www.mechion.com
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • cost reduction because less workforce is needed to monitor and observe patients
  • time reduction because the task of observing and monitoring becomes automated
  • better quality of service: assessments become more accurate and decions more informed due to big data acquisition
  • product could potentially be used in homes, thereby reducing the need of placing patients in facilities
  • earlier diagnosis could be possible, remote diagnosistics and low-cost observation regardless of facilities
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
  • better quality of service received, since more data is collected on a 24/7 basis
  • reduction of costs will allow care-workers and nurses to focus on more important tasks, thereby helping the patients more
  • better and earlier diagnostics can potentially help patients sooner
  • patients could avoid hospitalisation, and be monitored from home
Current and planned activity: 
We are currently engaging international organisations (research clinics and Universities) but are looking for early adopters in the Midlands. We have interviewed and identified key problems and issues we can solve with machine learning and AI and are now moving into prototyping. We should have a beta product ready for testing end of September.
What is the intellectual property status of your innovation?:
Software and Hardware
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Read more
Hide details
Alexandros Gkiokas 16/05/2018 - 12:50 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our web based visualisations of NHS datasets is disrupting the analytics market. It allows systems to understand cause and effect within their health economies and test hypothesis in real time by interacting with the data through drop down menus
Overview of Innovation:
Our vision is to give every NHS system leader in England a clear picture of the end to end journey for the populations they serve. At the same time we aim to save the NHS £millions by disrupting the market for low level analytics!
The challenge currently faced by all healthcare leaders is a lack of insight and meaningful, consistently-reported analysis regarding the position and performance of the healthcare system. This lack of insight hampers the efficacy of the strategic and operational planning process and the scope and effectiveness of monitoring and oversight.
This challenge sits in the context of masses of existing publicly available healthcare data. Data that’s time consuming for providers to prepare but underutilised due to its format, shape and local capacity and capability.
Our vision is to make VUIT.ONLINE, our information and insight portal, available across the entire NHS in England. The tools we’ve developed allow users to interrogate data across an provider, CCG, ST or ICS quickly and efficiently in a way which informs decision making and allows the impact of interventions to be validated using existing national datasets.
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
Our front-end combines different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through an online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses.The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource in the form of consulting and CSU costs which currently run into many millions.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
We do this in a pre-packaged but evolving, continuously-updated front-end combining different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through a scalable online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses at system level from the system’s own, current data within existing national datasets.
The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource. A fundamental success factor for the implementation of this innovation is a reduction in the cost of low-level analytical support to the NHS in the form of consulting and CSU costs which currently run into many millions.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
By giving system leaders the tools they require to effectively build end to end, whole system pathways and commission them outcomes will improve for the people of the West Midlands. However the way in which our innovation VUIT.Online is configured this benefit is freely available to all health economies in England
Current and planned activity: 
We are currently mid way theought the second wave of Test Bed applications where we are both an innovator and a defined test bed partner with a West Midlands CCG
What is the intellectual property status of your innovation?:
VUIT. Online and it's intellectual property is owned by its co-founders. It is built on licenced propriatry software and uses national data sets which exist in the public domain
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
VUIT. Online uses national data sets, propriatery analytcal software and globally recognised web developer frameworks (wordpress). As such it is scaleable across the entire NHS in England immediately
Measures:
Measurable outcomes:
-reduction in spend on low level analytics in the NHS in england
-reduction in patient pathway costs as health economies understand whole system costs more effectively and plan ICS's on this basis
-Improved ability to scale innovation in healthcare by giving innovators access to data which will support, clarify and stratify the way in which they develop and take their products to market
Adoption target:
We aim to make the resource available to all NHS managers in England through sharing examples of best practice around the use of VUIT.Online
Read more
Hide details
Adam Townsend 25/04/2018 - 14:31 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Omnigen® is a unique ‘off-the-shelf’ transportable biological matrix that can be used as an effective surgical and in clinic regeneration therapy for a range of wound care and ocular surface disorders.
Overview of Innovation:
The ocular surface comprises the cornea, conjunctiva, eyelids and lacrimal glands, and any disorder in these structures can be classified as an ocular surface disorder (OSD). Though the prevalence of OSD is quite high, unfortunately, cases often go undiagnosed or undertreated, due to a lack of understanding of symptoms and inaccurate evaluation. As people are living longer, these disorders are becoming more prevalent, but awareness about them is limited.
 
Omnigen is an innovative sight saving and wound care regenerative therapy that retains the natural regenerative properties of fresh amniotic membrane (amnion) in a dry and stable transplant matrix. Omnigen equips civilian and military clinicians with an easy accessible and easy to use regenerative therapy, allowing them to effectively treat OSD and trauma in surgery, in the clinic or in the emergency room.
 
Omnigen is supplied in a bespoke delivery tray. It is easy to manipulate and applied dry, directly to the eye, where it can be rapidly rehydrated by ambient in vivo moisture of the eye. The epithelial side is marked for confident orientation.
 
Omnigen contains no viable cells. It is stored and shipped at room temperature (25˚C) and is ready to use straight from the sterile pack. There is no longer any need to be concerned with keeping amnion frozen, thawing it, having to pre-plan use or risk wastage.
 
Omnigen retains the originality of amnion. It is manufactured using a patented preparation and drying process (Tereo®). This process allows retention of the natural trophic components present in fresh amnion; an element believed to be linked to wound healing performance (Allen C.L., et al 2013).
 
Omnigen is a stable matrix developed so that it may be stored at the point-of-care. As a stock product, it is therefore ready to use immediately when clinically required. Omnigen can thus be routinely accessed in emergency situations to treat the diseased ocular surface.



Omnigen is processed from amnion donated by UK donors undergoing elective caesarean section births at NHS hospitals. Donor eligibility is assessed via the donor’s history, a face-to-face medical/social history interview and mandatory blood tests. Omnigen is aseptically processed under Grade A clean room conditions and undergoes antibiotic decontamination. The culture negative microbiological status of the processed product is validated by an independent laboratory prior to release.


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Innovation and adoption
Benefit to NHS:
OSD (front surface of the eye) include a profile of blinding conditions that affect the cornea and conjunctiva. Omnigen is a sight saving and wound care regenerative therapy that is extremely convenient, easy-to-use, and effective in the treatment of OSD.

Why is amnion special: 

Amnion is the avascular inner layer of the foetal membrane which surrounds and protects the foetus during pregnancy. The amnion produces important proteins responsible for promoting the normal growth and development of the foetus [1]. 

These proteins exhibit immuno-regulatory [2, 3], anti-fibrotic [4, 5], anti-inflammatory, anti-angiogenic [6, 7] and wound healing characteristics. When appropriately preserved, the beneficial effects promoting wound healing can be maintained [8] to support improved regeneration of healthy tissue. Further to this, the foetal derived tissue [9] is immune privileged and therefore delivers a low risk of immunogenicity [2, 6].
 
Amnion has been successfully utilised for decades as an effective surgical adjunct for a wide variety of indications. However, its full potential has been limited due to its perishability, logistic challenges, and variability in the quality from piece to piece.
 
When applying the Tereo process to amnion, the amnion is carefully isolated from the placental mass with gentle ‘hands-free’ cleaning of the tissue to effectively remove any blood contamination. The process then implements proprietary steps to completely remove the irregular and inhibitory jelly-like substance on the stromal aspect of the amnion, the ‘spongy layer’. Researchers at Nottingham was the first to fully recognise the importance of removing the spongy layer, and therefore patented this process. The delicate Tereo drying procedure is a patented process that uniquely preserves the full complement of the aforementioned characteristics to deliver a high quality and enhanced therapy to the wound.
 
An extended series of Omnigen product sizes further allows surgeons to tailor their requirements on a patient-by-patient basis. This saves time previously spent adjusting the disc to fit the case, and reduces the amount of amnion that is to be discarded.
 
Currently, Omnigen is used surgically to treat OSD in hospitals UK-wide as a low-volume therapy. Our recent innovation to this is a novel surgical-free in-clinic application (OmniLenz®) that presents a unique opportunity to apply and retain Omnigen at the ocular surface without the need for surgery.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Corneal scarring where the clear window of the eye becomes damaged from infection or inflammation is a leading cause of blindness worldwide. The cornea provides both protective and refractive properties essential for sight.
 
Treatment of OSD in the UK is the current target market. OSD requiring surgical intervention accounts for >700,000 cases annually. 12-13% of eye-emergency cases have corneal damage, and at an NHS emergency department, 6% (123,697) of cases were eye-related, 80% (96,048) of which were corneal abrasions or foreign body-related. Clinical opinion leaders estimate that with strategic clinical development, education, and training, the total market potential is £125 million, of which NuVision could access 26% or 101,681 cases (£33 million) annually, within 5-years. 
 
Historically, clinicians have faced major practical, and logistical hurdles when it comes to accessing amnion. Typically, amnion is stored frozen at -80°C. Shipping is an expensive challenge and the end user must use or dispose of the tissue within 48 hours of receipt. It is therefore not possible to stably transport the processed tissue over large areas, and access to remote and developing regions, where it is most needed is greatly restricted.
 
Omnigen is dry-preserved amnion, which can be easily stored and shipped at room temperature, and has a long shelf-life. Omnigen can therefore be shipped and accessed in any clinical environment, where can be used directly or stored for when it is needed. The outer packaging contains an inner sterile packet which is easily accessible and the disc is available for immediate use.  Omnigen will rehydrate with the fluid on the eye surface once applied.
 
The technology behind Omnigen has been developed to optimize convenient use for a diverse range of indications. Furthermore, Omnigen is pre-cut into discs, saving preparation time and reducing amniotic tissue waste, this could save resources from a two-fold perspective.
 
Omnigen is licensed for human application under the HTA, and is implemented, and priced, as a surgical adjunct in hospitals across the UK, this provides low barriers to implement its wider use. It is currently being used to treat patients across 30 NHS hospitals and private clinics, offering fast access to proven pain reliefOmnigen now has the potential to facilitate a faster response time to emergency cases, or response vehicle for immediate emergency use. 
 
Current and planned activity: 
NuVision has demonsrated clinical and commercial proof-of-concept with Omnigen in ophthalmology units of over 50 hospitals; a further 130 are being set up.  

 Required activity :
  • Complete set up of ALL NHS hospitals: Implementing NuVision onto procurement is a major barrier to Omnigen adoption.
  • Replace frozen amnion use: Requires educational development.
  • Broaden Omnigen application potential: Requires educational development.
The next clinical focus is chronic wounds; expanding Omnigen into a much larger therapeutic market would empower practice changing strategies to treat wounds more proactively and efficiently to help sustain a comprehensive high-quality NHS.
 
We are committed to continuously improving our market potential, and would be delighted to discuss usages and modifications of our current products for clinicians throughout the West Midlands to help develop an accurate business case acceptable to NHS trusts for implantation of Omnigen treatment solution.
What is the intellectual property status of your innovation?:
Background intellectual property (IP) pertaining to Omnigen development and manufacturing are the subject of a GB granted patent (GB2441939 - priority date 17-06-2006; granted 16-03-2011) and a GB priority (PCT) application PCT/GB2014/051722. The IP is owned by the University of Nottingham and exclusively licenced to NuVision, with freedom-to-operate.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Dr Andrew Hopkinson 18/04/2018 - 13:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Reduce the time it takes for clinicians to find clinical trial options for patients and increase trial enrollment rates.
Overview of Innovation:
It requires significant time to evaluate open clinical trials, analyse inclusion/exclusion criteria and determine a patient’s eligibility for trials based on all the relevant information in the medical record.
Watson for Clinical Trial Matching eliminates the need to manually compare enrollment criteria with patient medical data, making it possible to efficiently identify the potential trial options. It generates a ranked list of relevant trials for each patient

This increases patient access to clinical research, improves trial enrollment, and reduces trial delays.
See details and a video at: https://www.ibm.com/watson/health/oncology-and-genomics/clinical-trial-matching/
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Innovation and adoption
Benefit to NHS:
Saves time in evaluating Clinical Trials available to your patients and their eligibility. Improves Trial enrollment rates - making new treatments available quicker for patients.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Potential to be the first region in England to use this technology and make trials and new treatments available quicker for patients.
Current and planned activity: 
Currently deployed in healthcare outside UK. We are looking for organisations who will prove the solution works and delivers benefits in the UK.
What is the intellectual property status of your innovation?:
IP is IBMs
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
David Clarkson 26/02/2018 - 13:46 Publish 1 comment
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Watson for Genomics provides peer-reviewed, molecular evidence to help oncologists create personalized treatment strategies for patients based on results from genetic testing of tumour tissue.
Overview of Innovation:
Watson for Genomics analyses and categorizes genetic alterations that are related to cancer progression and provides a list of potential therapeutic options that target each alteration. The interpretation is done within minutes, and a comprehensive report is generated. The summary page of the report lists all the critical genetic alterations that were identified in the analysis and associates each with therapeutic options. Levels of evidence, extracted from relevant literature are provided to show the strength of the evidence.
Watson for Genomics presents findings with evidence via hyperlinks to sources for easy drill down. The drug report section provides details of identified drugs with overview, rationale for the association and level of evidence, as well as recruiting clinical trials.
The molecular profile interpretation provides in depth detail of the known genetic alterations found in the tumour sample. For each mutation, molecular and scientific evidence explaining the pathologic relevance of the alteration is provided. The diagram offers easy viewing of mutations with chromosomal location.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine
Benefit to NHS:
As sequencing becomes more cost-effective, larger gene panels/whole exomes and whole genomes will gain more traction. However, analysis of these will be a challenge, especially using manual methods of curation. Providing rapid cognitive insights to a molecular pathologist will allow genomic testing to become more pervasive and scalable.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
In conjunction with the West Midlands Centre for Genomic medicine, Watson for Genomics will allow genomic testing and personalised treatment options to become more pervasive and scalable in the West Midlands.
Current and planned activity: 
Watson for Genomics is deployed in US. We are currently discussing with several UK Trusts how to bring and prove it in the UK.
What is the intellectual property status of your innovation?:
IP of core product is IBM's
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
David Clarkson 26/02/2018 - 12:26 Publish Login or Register to post comments
3
1
Votes
-99999
Innovation 'Elevator Pitch':
An online platform to recruit doctors and nurses for locum/temp shifts, and permanent shifts.  
Overview of Innovation:
MedicBank is an online platform to recruit locum and permanent nurses/doctors to hospitals, cutting the current high costs associated with traditional agencies. Nurses and doctors will be able to select shifts at immediate and elective notice, and matching AI software will aid this process to improve links between staff managers and their staff. This AI component will also help hospitals better understanding pricing by: times of the day, seasonal holidays, position and urgency.

The platform has been designed to improve the usability and interface between hospitals, their staff and future hires. Maintaining a real-time focus on intelligent pricing strategies and demand planning backed by our custom big data algorithms. The impact of this is seen on healthcare delivery. Hospitals will save a lot of money through our novel billing system, and this means that they can spend more directly on healthcare provisions. Furthermore, as a result of better staffing, patients will be seen sooner and should receive a higher quality of care.
 
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Wealth creation
Benefit to NHS:
MedicBank has multiple benefits:
- Significantly more cost effective (up to 40%) due to our novel billing system
- Cheaper than existing traditional agencies
- Help solve short-term staffing problems (locum and temporary staff) as well as long-term recruitment issues (permanent staff)
- It targets both doctors and nurses. Other organizations have avoided focuses on nurse recruitment as this has significantly more administrative barriers to market.
- It reallocates the distribution of power from staff agency firms to the hospitals through unique features.
- This digitalizes the process of international recruitment of staff to help solve the issues underlying the staffing crisis.
Initial Review Rating
3.40 (2 ratings)
Benefit to WM population:
The societal need is a general improvement in healthcare provision. This includes:
o Reducing waiting times for emergency and elective procedures. More staffing in emergency departments will aid patients being seen within a reasonable time. This has further implications for elective procedures also.
o A higher quality of care that is associated with a fully-staffed healthcare team. When a ward is fully staffed, then patients receive a greater amount of care as there are more people to provide it. This means more time for patients.
o More available options due to reduced spending on staff (a lot of which goes to agencies and not to the staff). Trusts are limited by their capital and equipment, this leads to greater waiting times for patients.
o Happier staff will deliver better care. The current mood within the medical workforce is poor. They feel over-worked and targeted, and it is difficult for this not be translated into their work mood.
Current and planned activity: 
Our current plans are to engage with AHSN that are nearby to our current location (East Anglia/London) to try and commence procurement. 
What is the intellectual property status of your innovation?:
Code, AI, and undisclosed features are our IP.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Fawz Kazzazi 22/02/2018 - 18:27 Publish Login or Register to post comments
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Feedback Centre enables organisations to collect feedback from any stakeholder. This information is presented via a visual dashboard called Informatics, allowing health organisations to spot trends & issues and act on them or plan improvements.
Overview of Innovation:
Feedback Centre has been developed in collaboration with and for the NHS and Health & Social Care organisations.

Feedback Centre brings together public feedback, survey results and complaints, all of which can be shared directly with stakeholders/service providers. This allows data from multiple sources to be joined-up, stored in one place and shared organisation-wide. 

Feedback can be collected online, including by tablet, mobile, Facebook and via widget, as well as via SMS and kiosk. This offers a great choice for patient engagement and allows patient experience teams to gain information from a broad cross-section of society, as different social, economic and clinical groups often communicate via very different means. The system also allows offline and archived feedback collected from other sources to be imported into Feedback Centre.
                                                                                                           
Feedback Centre also includes a screen-reading and translation feature with the aim of preventing the exclusion of those with visual impairments or poor literacy skills from engaging with providers.
 
Health & Service providers are able to respond publically to feedback, shortening response times to public concerns and reducing the volume of incidents that escalate to formal complaints.
 
Our business intelligence dashboard, Informatics, presents the fastest way possible for Health organisations/Trusts to access data, understand trends and create reports. It will also provide clients with the ability to utilise their own taxonomy, categorising the data in any format required. This allows for benchmarking of providers, services and departments, as well as identifying areas for potential improvement.

Utilising sentiment analysis, Feedback Centre will determine the emotional tone behind a series of words. This can be used to gain an understanding of the attitudes, opinions and emotions expressed within a review or complaint. Thus they can be weighted for seriousness and therefore flag providers to take note and take instant action
 
To ensure confidentiality the system is hosted by EKKO securely to NHS Trust information governance standards with monthly updates provided to the platform. 
 
To see Feedback Centre in action, take a look at the following video featuring Healthwatch and NHS England: http://www.EKKOmedia.com/healthwatch-video/
 
Benefits:
  • Branded system for any organisation
  • All information available in one place
  • Secure, ISO27001 Hosted Surveys and GDPR ready
  • Less risk, all information is shared directly with client only
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
A single database for ALL experience data: The key benefit to the NHS is the storage of all user & staff experience data into a single database, which can be, used organisation-wide by an unlimited number of users with different levels of access. Hence this aggregation of data provides:

A facility removes the risk of inefficiencies due to having multiple, unconnected silos of disparate information, training is provided every step of the way by EKKO.
  • Peace of mind for GDPR compliance and ISO27001 hosting, utilising world leading hosting architecture Amazon Web Services.
  • An ability to create a snapshot or larger historic overviews of analysed data on single aspects or wider views of experiential data and trust feedback    
  • Services and providers to be benchmarked, allowing the identification of top performers or highlighting underperforming providers or departments. Alternatively it can show issues where quality or care does not match KPI’s, indicating a need for investigation or a comparison to be made. 
     
  • Creation of specific taxonomies; Trusts can categorise their data to ensure that the words and meanings meet that of their patients within in different clinical, social and ethical groups, so as to remove barriers whilst ensuring data integrity and meaning is maintained when analysed and reported on.
     
  • Through the multi-channel approach it allows Inclusivity and increased response rates while maintain data cohesion. Feedback Centre can be used to engage with a broader cross-section of society, resulting in higher response rates for surveys. e.g. young people and those within the working population are often unable to attend Patient Participation Group (PPG) meetings, meaning they are often under or not represented in survey results. Allowing those groups to complete a survey via a smartphone or Facebook application which increases the likelihood of gaining a more representative sample within the Feedback Centre database.
     
  • Cost savings on external surveys suppliers - The system can be used to administer the Friends and Family Test, as well as any other mandatory or ad-hoc NHS surveys, including staff surveys. Using the system for surveys removes the need for external partners to conduct surveys, hence a significant saving. (The system has no limit on users or the creation of custom surveys, thus no additional costs per survey). Whilst also ensuring all survey data is held by the Trust and in one place for future reference and analysis.

Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
How do the public see their responses or outcomes/results of feedback they give?



Give YOUR Patients & the Public a voice for feedback and complaints
We provide the WM population with a place to share feedback safely about services that they use. All health and care providers can feature on the system. Feedback is displayed publicly after moderation, allowing anyone to compare and benchmark providers based on real experiences.
 
The system is multi-channel, inclusive and easy to use
A significant proportion of the NHS’s engagement is done via Patient Participation Groups (PPGs). PPGs are not always representative re: age, race & gender, as well as numerous other demographic factors. This is due to people being unable to attend PPG meetings due to being at work, school or condition they are being treated for. By offering a multi-channel solution, members of the public are able to leave feedback online, increasing the likelihood of gaining direct feedback and insights from those groups. A text-reader service can be added to the site to enable those with visual impairments and speakers of other languages to give feedback.
 
Our technology can be used to broaden ways users engage in feedback. Thus we wish to work with health providers to explore & develop such processes & systems.
 
Provider responses
Service providers are able to respond to reviews publically or privately, addressing concerns before they escalate into serious issues or formal complaints. This demonstrates to the public that they are being listened to, inspiring confidence in services & can be used to intervene in more serious alerts & complaints.

Branded, secure portal
The system is branded to health clients’ guidelines to ensure uses have confidence with whom they are engaging with and responding too. Security and hosting is to NHS Trust IG standards with Amazon Web Services. All data is hosted in the UK and load-balanced, ensuring availability of systems at all times.
 
Using a secure, online portal offers a greater level of security than collecting data offline/paper, as well as providing significant cost savings. Currently, most patient experience data is collected and stored offline in a multiple, which has implications in terms of the GDPR regulations that come into effect in May 2018.
 
Monitoring & reporting on changes
Centralisation of cohesive data provides the ability to compare and contrast between service, timeframes and as a way of gauging and monitoring any changes that are made.
 
Current and planned activity: 
Current
We work with NHS trusts, CCGs, Healthwatch network & local. System is showcased at UK events with major update due -Feedback Centre 2.0. Long term aims are to roll-out across NHS, Care & Housing sectors

Regional Scalability
Explore West Mids roll out as it has not yet been scaled across an entire NHS region previously. NHS E & SWAHSN funded regional roll-out across 7 Healthwatch network organisations
 
Individual CCG, Trusts, STP, Healthwatch & GP federations uses are possible. Regional or large scale adoption could provide individual as well as wider insights to services & their performance & satisfaction levels.
 
Wish to hear from
Organisations wanting Feedback Centre demo: - GP, CCG, Trust or other health/social care provider
 
Evaluation & Validation of system benefits, monitoring delivery, ensuring + patient experience
 
Product Development – expand ways patients can engage & provide feedback
 
What is the intellectual property status of your innovation?:
Feedback Centre is copyright protected, having been created by EKKO. Data held within the system is the IP of the client, with EKKO performing the role of data processor.

Regulatory Approvals:
EKKO hold the following approvals: 

Cyber Essentials: EKKO have completed Cyber Essentials, a Government-backed, industry-supported scheme to help organisations protect themselves against the most common threats found on the internet.

GDPR Foundation Certification – EKKO have completed this certification with the aim of helping our clients prepare for the new regulation requirements.

Data Protection Public Register: ZA310893
 
IG Toolkit – EKKO are currently working towards the IG Toolkit and aim to have this completed by April 2018. 
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Ian Hughes 15/02/2018 - 17:28 Publish 1 comment
5.5
2
Votes
-99999

Recent Activities

Anthony John Bartlett commented on One drop of blood to predict my future health & best ways to maintain it. 5 hours 18 min ago
Ravi Kumar commented on One drop of blood to predict my future health & best ways to maintain it. 4 days 23 hours ago
Ravi Kumar commented on One drop of blood to predict my future health & best ways to maintain it. 5 days 15 min ago
Chris Dyke commented on VIDIMO 1 week 2 hours ago
VIDIMO has been moved from Initial Submission to Publish 1 week 2 days ago

Active Campaigns